Jump to content
Otter

Pharmacogenetics influence on tapering

Recommended Posts

Otter

Hi all,

Is anyone familiar with pharmacogenetics and the influence of gene variation with the 5-HTT pathways on drug metabolism/half life/plasma concentration as it pertains to SSRI withdrawal? I have found a number of studies examining the effects of rapid metabolizing on drug concentration, but none examining the linkage to withdrawal syndrome. 

I have my raw genetic data file from a 23andme test I got as a gift some years ago and I like to go through and read SNP variants. I found out that I have a genetic predisposition for polycystic kidney disease this way, strangely enough. It's just that with immigrant parents who come from a third world country, if you maternal grandmother is the first person to survive past the age of 60, you just don't build up a family history of the diseases associated with aging (haha)....

Anyways, I happen to know that I have a few gene variants associated with an extensive/rapid metabolizer CYP2C19 enzyme (specifically CYP2C19*17 rs12248560). This enzyme is responsible for the breakdown of a number of different drugs - plavix, omeperazole, but also with a number of antidepressants (amitriptyline, citalopram, sertraline, etc). I understand that those who are ultrarapid metabolizers like myself may need larger doseges to achieve a treatment response.

This also leads me to wonder if the fast metabolizer would hit that wall that "uh oh" point that I have read about in other posts more rapidly, or at an earlier taper point, than those who are normal or inefficient CYP2C19 enzymatic activity.

Thanks in advance for any info! Cheers.

Share this post


Link to post
Share on other sites
Altostrata

There is no identifiable effect of pharmacogenetics on tapering. Each person has to find his or her individual most comfortable tapering schedule.

Share this post


Link to post
Share on other sites
Otter

There is no identifiable effect of pharmacogenetics on tapering. Each person has to find his or her individual most comfortable tapering schedule.

No existing/known effect but it has not been ruled out? 

 

I have be be specific in semantics because of my training, in my line of work if we say there is no identifiable effect, chances are no young researcher will attempt to discover if there actually is a relationship. And I certainly hope that if one exists, it is soon discovered, because more evidence from pharmacogenetics could greatly reduce the types of issues we see with SSRI therapy.

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×

Important Information

By using this site, you agree to our Terms of Use.